Clinical trial
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed…
NCT00093600 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00093600 |
|---|---|
| Title | PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
| Official title | A Phase IB, Open-Label Study to Determine the Safety and Pharmacokinetics of Twice Daily Oral Dosing of PKC412 Administered in Combinations Sequentially and Concomitantly With Daunorubicin and Cytarabine for Standard Induction Therapy, and High Dose Cytarabine for Consolidation in Patients With… |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia (AML) |
| Intervention type | Drug |
| Interventions | cytarabine, daunorubicin hydrochloride, midostaurin |
| Enrollment | 69 |
| Start date | Feb 1, 2004 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Oct 8, 2004 |
| Last update posted | Dec 19, 2020 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: